News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nvidia trading near $230 is presented as a buy due to its AI moat, cash flow and a $150B share buyback.
  • Anthropic's reported $110B commitment to cloud and chips strengthens AWS's competitive moat and supports a long Amazon trade.
  • Estée Lauder's fiscal Q4 beat, $1.2B cost savings, and stronger margin guide indicate a progressing turnaround and upside potential.
  • NextPower recommended as a tactical 45-day long with entry $4.50, target $6.50 and stop $3.75.
  • EXL's seventh sustainability report details GHG reductions, increased renewable energy use, volunteerism, and responsible AI governance.
  • WTW partners with Sapien to add AI-enabled HR and deal intelligence to its DIAB offering for mid-market divestitures and M&A.

Latest Articles

APA Corporation provides second-quarter 2026 supplemental information and schedules results conference call for Aug. 6 at 10 a.m. Central time

APA Corporation provides second-quarter 2026 supplemental information and schedules results conference call for Aug. 6 at 10 a.m. Central time

APA Corporation released supplemental information related to its second-quarter 2026 financial and operational estimates, including production curtailment updates and average realized commodity prices. The company announced an upcoming earnings conference call on August 6 to discuss final results. The information aids investors in forming estimates…

Inuvo Releases New Investor Presentation

Inuvo Releases New Investor Presentation

Inuvo, Inc., a provider of AI advertising technology, released an updated investor presentation detailing its IntentKey AI strategy, market opportunities, and growth plans. The presentation outlines Inuvo's competitive advantages in programmatic advertising, highlighting its proprietary large language model that predicts consumer intent without usi…

Simulations Plus CRO John DiBella Executes $18,360 Stock Sale Amid Acquisition Talks and Earnings Preview

Simulations Plus CRO John DiBella Executes $18,360 Stock Sale Amid Acquisition Talks and Earnings Preview

John Anthony DiBella II, serving as Chief Revenue Officer for Simulations Plus, Inc. (NASDAQ: SLP), disposed of 1,000 shares of the company's common stock on July 6, 2026. The transaction totaled $18,360 and was executed through multiple sales priced between $18.34 and $18.39 per share. The sale was conducted automatically under a Rule 10b5-1 tradi…

Monster Beverage Declares Two-for-One Stock Split

Monster Beverage Declares Two-for-One Stock Split

Monster Beverage Corporation's Board of Directors declared a 2-for-1 stock split to be effected as a 100% stock dividend, rewarding shareholders with additional shares and increasing stock liquidity. The split will be distributed to shareholders of record on July 24, 2026, with shares trading at the adjusted price starting August 11, 2026.

Insmed CMO Martina Flammer Executes Pre-Arranged Stock Transactions

Insmed CMO Martina Flammer Executes Pre-Arranged Stock Transactions

Martina M. Flammer, Chief Medical Officer at Insmed Incorporated (NASDAQ: INSM), executed a series of stock transactions on July 6, 2026, selling approximately $1.35 million worth of company shares. The sales were conducted under a pre-arranged 10b5-1 trading plan adopted in February 2025. Concurrently, Dr. Flammer exercised stock options to acquir…

Vaxcyte to Participate in Upcoming Investor Conferences

Vaxcyte to Participate in Upcoming Investor Conferences

Vaxcyte, Inc., a clinical-stage US vaccine company, announced its participation in upcoming investor conferences where it will present its pipeline of advanced vaccine candidates. Their lead candidates, VAX-31 and VAX-24, target broad protection against invasive pneumococcal disease, with additional vaccines in development including VAX-A1 for Grou…